Literature DB >> 10326959

VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma.

C C Chan1, A O Vortmeyer, E Y Chew, W R Green, D M Matteson, D F Shen, W M Linehan, I A Lubensky, Z Zhuang.   

Abstract

OBJECTIVE: Retinal angioma frequently occurs in von Hippel-Lindau (VHL) disease. However, VHL gene alterations have not been documented in retinal angiomas.
METHODS: Using tissue microdissection and polymerase chain reaction amplification, we have analyzed 7 retinal angiomas associated with VHL disease for loss of heterozygosity of the VHL gene. In addition, vascular endothelial growth factor expression was evaluated in these tumors by immunohistochemistry and in situ hybridization.
RESULTS: All 6 informative retinal angiomas showed loss of heterozygosity of the VHL gene. Loss of heterozygosity was detected in vacuolated "stromal" cells, but not in vascular cells or reactive glial tissue. Vascular endothelial growth factor protein and messenger RNA were also present in vacuolated "stromal" cells.
CONCLUSIONS: These findings suggest that vacuolated "stromal" cells represent the true neoplastic component in retinal angioma. These cells express vascular endothelial growth factor and therefore may be responsible for abundant neovascularization of retinal angioma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326959     DOI: 10.1001/archopht.117.5.625

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  33 in total

1.  Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma.

Authors:  Vincenzo Russo; Andrea Stella; Antonio Barone; Ingrid U Scott; Nicola Delle Noci
Journal:  Int Ophthalmol       Date:  2012-01-22       Impact factor: 2.031

2.  Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma.

Authors:  Yujuan Wang; Mones S Abu-Asab; Defen Shen; Zhengping Zhuang; Emily Y Chew; Chi-Chao Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-24       Impact factor: 3.117

Review 3.  [Retinal angiomatosis. Ocular manifestation of von Hippel-Lindau disease].

Authors:  B Junker; D Schmidt; H T Agostini
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

Review 4.  Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Authors:  Chi-Chao Chan; Atif Ben Daniel Collins; Emily Y Chew
Journal:  Retina       Date:  2007-01       Impact factor: 4.256

5.  Retinal Reactive Astrocytic Tumor (Focal Nodular Gliosis): The Entity Also Known as Vasoproliferative Tumor.

Authors:  Hans E Grossniklaus; Tamara L Lenis; Frederick A Jakobiec
Journal:  Ocul Oncol Pathol       Date:  2017-01-26

6.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene.

Authors:  Yasuhiro Miyagawa; Mitsuru Nakazawa; Yasuko Noda; Shoichi Ito; Hiroshi Ohguro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-20       Impact factor: 3.117

Review 8.  Central nervous system capillary haemangioblastoma: the pathologist's viewpoint.

Authors:  Mahmoud R Hussein
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

9.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

10.  Retinal function in the von Hippel-Lindau disease.

Authors:  Wojciech Lubiński; Karol Krzystolik; Cezary Cybulski; Zbigniew Szych; Krzysztof Penkala; Olgierd Palacz; Jan Lubiński
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.